Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on June 5, 2026, to vote on three key items. Stockholders will elect three Class III directors to serve until the 2029 meeting, ratify Ernst & Young LLP as independent auditor for 2026, and cast a non-binding advisory vote on executive compensation. Holders of 125,073,249 shares of common stock as of April 8, 2026 may vote, with one vote per share. The board highlights its largely independent, skills-diverse membership, describes its committee structure and risk oversight approach, and outlines pay, governance, ESG, and stock ownership practices in detail.
Arcutis Biotherapeutics director Howard G. Welgus reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $23.8801 per share. After this transaction, he directly holds 39,744 shares of Arcutis common stock.
The sale on April 1, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The shares were sold in multiple trades at prices ranging from $23.61 to $24.12 per share.
Arcutis Biotherapeutics (ARQT) reported proposed sales of Common Stock under a Form 144 by Howard Welgus. The filing lists two recent dispositions: 10,000 shares sold on 03/02/2026 for $256,517.50 and 10,000 shares sold on 02/02/2026 for $250,482.69. The notice also references 10,000 shares tied to a prior stock option exercise on 06/04/2018.
Arcutis Biotherapeutics Inc ownership update: The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock, representing 0%. The filing cites an internal realignment on January 12, 2026 and disaggregation of subsidiary holdings in accordance with SEC Release No. 34-39538.
The form is signed by Ashley Grim, Head of Global Fund Administration, on March 26, 2026.
Arcutis Biotherapeutics director Leonard Keith R reported a mix of stock option exercises and share sales in Arcutis Biotherapeutics, Inc. He exercised fully vested stock options for 27,052 and 12,220 shares of common stock at exercise prices of $8.63 and $7.51 per share, respectively, on March 2, 2026. On the same day, he sold 39,272 shares of common stock in open-market transactions at a weighted average price of $25.392 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2025 with an end date of February 16, 2027. After these transactions, he directly owned 22,123 Arcutis shares and an additional 1,750 shares were held indirectly by the Leonard Family Trust, for which he is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock in an open-market transaction. The sale took place on March 2, 2026 at a weighted average price of $25.6518 per share, in multiple trades between $25.37 and $26.10. After this sale, he directly owned 49,744 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025 with an end date of May 29, 2026.
Arcutis Biotherapeutics officer Larry Todd Edwards reported both stock sales and new equity awards. On March 2, 2026, he executed open-market sales totaling 3,687 shares of common stock at weighted average prices around the mid‑$20s per share to cover tax withholding obligations tied to vested restricted stock units.
On February 27, 2026, he received a grant of 77,000 stock options and a separate award of 30,000 restricted stock units, both at a reported price of $0.0000 per share. Following these transactions, his direct common stock holdings were reported at 175,178 shares, and the new options will vest monthly over four years starting March 1, 2026.
Arcutis Biotherapeutics director and officer Todd Watanabe reported a mix of stock sales and new equity awards. On March 2, 2026, he sold a total of 37,349 shares of common stock in open-market transactions at weighted average prices of $25.1606 and $25.9139 per share. A footnote states these shares were sold to cover tax withholding obligations related to vesting restricted stock units (RSUs).
On February 27, 2026, he received an option covering 266,000 shares, vesting monthly over four years starting March 1, 2026, and a grant of 102,000 RSUs, vesting 25% annually each March 1 beginning in 2027. The filing also notes additional shares held by several trusts and an LLC, for which he disclaims beneficial ownership beyond any pecuniary interest.
Arcutis Biotherapeutics executive Masaru Matsuda reported a mix of stock sales and equity awards. On March 2, 2026, he sold a total of 12,058 shares of common stock in open-market transactions at weighted average prices around $25–$26, under a Rule 10b5-1 trading plan ending on September 4, 2026. Some sales are described as covering tax withholding obligations from restricted stock unit vesting. Following these sales, he continued to hold over 130,000 shares directly.
On February 27, 2026, Matsuda received equity compensation, including 97,000 stock options and 37,000 restricted stock units. The options vest monthly over four years starting March 1, 2026, and the RSUs vest 25% annually each March 1 beginning in 2027, contingent on continued service to the company.
Arcutis Biotherapeutics, Inc. SVP and Chief Financial Officer Latha Vairavan reported both stock awards and small share sales. On February 27, 2026, she received grants of 27,000 Restricted Stock Units (RSUs), each convertible into one common share, vesting 25% annually starting March 1, 2027, and a stock option for 70,000 shares that vests monthly over four years from March 1, 2026.
On March 2, 2026, she sold a total of 2,853 common shares in open‑market transactions at weighted average prices of $25.1605 and $25.9140 per share, in price ranges disclosed in the footnotes, to cover tax‑withholding obligations upon RSU vesting. After these sales, she directly held 87,754 common shares.